# Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

- Link: https://www.directorstalkinterviews.com/avacta-group-antigen-distribution-agreement-and-potential-treatment-for-covid-19-interview/412823611
- Published: 2020-05-20T11:20:07+01:00
- Author: Giles Arbor

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l))
CEO Alastair Smith joins DirectorsTalk to discuss a [distribution agreement](https://www.directorstalkinterviews.com/avacta-and-medusa19-enter-into-a-distribution-agreement-for-covid-19-antigen-test/412823550)
with Medusa 19 for its rapid antigen test direct to consumer. Alastair talks us 
through this latest news, provides an update on the development of the tests and
provides details around the potential Affimer treatment for COVID 19.

Avacta Group’s Affimer platform is an alternative to antibodies derived from a small
human protein. Despite their shortcomings, antibodies currently dominate markets
worth in excess of $100bn. Affimer technology has been designed to address many 
of these negative performance issues, principally: the time taken, and the reliance
on an animal’s immune response, to generate new antibodies; poor specificity in 
many cases; large size and cost.

Share on:
